The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Recent clinical guidelines have emphasized the importance of screening for cognitive impairment in older adults with diabetes, however, there is still a lack of understanding about the drug therapy. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used in the treatment of type 2 diabetes and potential applications may include the treatment of obesity as well as the adjunctive treatment of type 1 diabetes mellitus in combination with insulin. Growing evidence suggests that GLP-1 RA has the potential to treat neurodegenerative diseases, particularly in diabetes-related Alzheimer's disease (AD) and Parkinson's disease (PD). Here, we review the molecular mechanisms of the neuroprotective effects of GLP-1 RA in diabetes-related degenerative diseases, including AD and PD, and their potential effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An increase in oxidative stress and ROS production play a role in mitochondrial DNA damage, respiratory impairment, and calcium imbalance, where all these symptoms of mitochondrial dysfunction are associated with AD. 93”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neurodegeneration and cognitive deterioration can be influenced by the brain’s GLP-1 secretion and its peripheral in those affected by diabetes; however, external GLP-1 treatment may prove advantageous.92,93”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredIn the citing paper
“All GLP-1RAs have been found to cross the blood–brain barrier (BBB) and stimulate GLP-1 receptors in the brain, thus offering neuroprotection [17].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Paladugu, L., Gharaibeh, A., Kolli, N., Learman, C., Hall, T. C., Li, L., Rossignol, J., Maiti, P., & Dunbar, G. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020860 · Cited by 80
RetractedLiraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway
Qiao, H., Ren, H., Du, H., Zhang, M., Xiong, X., & Lv, R. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8371 · Cited by 79
RetractedLi, J., Li, N., Yan, S., Lu, Y., Miao, X., Gu, Z., & Shao, Y. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9946 · Cited by 19
RetractedEndoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes
Özcan, U., Cao, Q., Yilmaz, E., Lee, A.-H., Iwakoshi, N. N., Özdelen, E., Tuncman, G., Görgün, C., Glimcher, L. H., & Hotamisligil, G. S. (2004) · Science · doi:10.1126/science.1103160 · Cited by 3,844
Crosstalk of reactive oxygen species and NF-κB signaling
Morgan, M. J., & Liu, Z.-G. (2011) · Cell Research · doi:10.1038/cr.2010.178 · Cited by 3,505
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H. P., & Ron, D. (2000) · Science · doi:10.1126/science.287.5453.664 · Cited by 2,988
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 1×
“In AD, Aβ damages microglia, produces inflammatory cytokines and chemokines, and affects surrounding CNS resident cells (astrocytes, oligodendrocytes, and neurons), which may aggravate tau pathology and ultimately lead to neurodegeneration and neuron loss.(166) Inflammation may also be a potential link between diabete…”
BackgroundNew neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?
Deng, W., Aimone, J. B., & Gage, F. H. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2822 · Cited by 2,120 · cited 1×
“The integration of adult-born neurons into the circuitry of the adult hippocampus suggests an important role for adult hippocampal neurogenesis in learning and memory.(103) The insulin/insulin-like growth factor (IGF) pathway promotes NSCs proliferation, differentiation, and survival;(104) therefore, impaired insulin…”
Background
Research works printed but not linked: 3
- Youssef, 2009, West Indian Med J, 58, 410
- Qi, 2017, Am J Transl Res, 9, 247
- Egefjord, 2012, Dan Med J, 59, A4519
Cited by
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
“GLP-1 therapy decreased IL-1b mRNA production compared to the LPS alonetreated cultures (67, 72).”
BackgroundMetabolic memory: mechanisms and diseases
Dong, H., Sun, Y., Nie, L., Cui, A., Zhao, P., Leung, W. K., & Wang, Q. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01755-x · Cited by 213
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes
Monney, M., Jornayvaz, F. R., & Gariani, K. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101470 · Cited by 91
Rhea, E. M., Babin, A., Thomas, P., Omer, M., Weaver, R., Hansen, K., Banks, W. A., & Talbot, K. (2024) · Tissue Barriers · doi:10.1080/21688370.2023.2292461 · Cited by 81
True or false? Alzheimer’s disease is type 3 diabetes: Evidences from bench to bedside
Peng, Y., Yao, S.-Y., Chen, Q., Jin, H., Du, M., Xue, Y.-H., & Liu, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102383 · Cited by 96
Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
“All GLP-1RAs have been found to cross the blood– brain barrier (BBB) and stimulate GLP-1 receptors in the brain, thus offering neuroprotection [17].”
BackgroundKong, F., Wu, T., Dai, J., Zhai, Z., Cai, J., Zhu, Z., Xu, Y., & Sun, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205207 · Cited by 54
Type 2 Diabetes and Alzheimer’s Disease: The Emerging Role of Cellular Lipotoxicity
Marrano, N., Biondi, G., Borrelli, A., Rella, M., Zambetta, T., Gioia, L. D., Caporusso, M., Logroscino, G., Perrini, S., Giorgino, F., et al. (2023) · Biomolecules · doi:10.3390/biom13010183 · Cited by 51
Lin, M.-H., Cheng, P.-C., Hsiao, P.-J., Chen, S.-C., Hung, C.-H., Kuo, C.-H., Huang, S.-K., & Clair Chiou, H.-Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109653 · Cited by 42
Lisco, G., Tullio, A. D., Iovino, M., Disoteo, O., Guastamacchia, E., Giagulli, V. A., & Triggiani, V. (2023) · Biomedicines · doi:10.3390/biomedicines11112993 · Cited by 54
Sinclair, A. J., Pennells, D., & Abdelhafiz, A. H. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02142-8 · Cited by 47
Singh, D. D., Shati, A. A., Alfaifi, M. Y., Elbehairi, S. E. I., Han, I., Choi, E. H., & Yadav, D. K. (2022) · Cells · doi:10.3390/cells11233767 · Cited by 46
From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics
Roy, A., Dawson, V. L., & Dawson, T. M. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00712 · Cited by 47
Mi, R., Cheng, H.-F., Chen, R., Bai, B., An, L., Gao, F., & Xue, G. (2024) · Brain Circulation · doi:10.4103/bc.bc_38_24 · Cited by 39
Oumata, N., Lu, K., Teng, Y., Cavé, C., Yu, P., Galons, H., & Roques, B. P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114578 · Cited by 38
Nassar, M., Nassar, O., Abosheaishaa, H. M., & Misra, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02466-4 · Cited by 35
Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord
Lee, S.-O., Kuthati, Y., Huang, W.-H., & Wong, C. (2024) · Cells · doi:10.3390/cells13221857 · Cited by 46
Zhang, P., Mao, C., Sun, A., Yang, Y., Hou, Y., Fu, Z., Tousi, B., Leverenz, J. B., Pieper, A. A., Luo, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70639 · Cited by 33
González-Bautista, E., Momméja, M., Mauléon, A. D., Ismail, Z., Vellas, B. J., Delrieu, J., & Martín, M. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13902 · Cited by 29
Vandersmissen, J., Dewachter, I., Cuypers, K., & Hansen, D. (2025) · Sports Medicine - Open · doi:10.1186/s40798-025-00836-7 · Cited by 33
Unlocking Longevity with GLP-1: A Key to Turn Back the Clock?
Chavda, V. P., Balar, P. C., Vaghela, D. A., & Dodiya, P. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108028 · Cited by 24
Colin, I. M., Szczepanski, L. W., Gérard, A.-C., & Elosegi, J. A. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.16 · Cited by 29
Doucet, J., Gourdy, P., Meyer, L., Benabdelmoumene, N., & Bourdel‐Marchasson, I. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s423122 · Cited by 33
Liu, T., Fan, Z., Li, Y., Xiao, B., & Chang, H. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133229 · Cited by 25
Exendin‐4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease
Verma, A., Chaudhary, S., Solanki, K., Goyal, A., & Yadav, H. N. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14426 · Cited by 24
Magdy, Y., Kamar, S. A., Habib, M. Z., Rady, H. Y., Rabei, M. R., & Khedr, S. A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06834-7 · Cited by 24
Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., Barbato, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011299 · Cited by 23
Cozza, A., Chinigò, C., Filicetti, E., Greco, G. I., Lappano, R., Marinaro, C., Muglia, L., Soraci, L., Corsonello, A., Lattanzio, F., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102834 · Cited by 20
Wolfram Syndrome 1: A Pediatrician’s and Pediatric Endocrinologist’s Perspective
Serbis, A., Rallis, D., Giapros, V. I., Galli‐Τsinopoulou, A., & Siomou, E. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043690 · Cited by 16
Role of mitogen-activated protein kinase inhibitors in Alzheimer's disease: Rouge of brain kinases
Almasoudi, S. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Eliwa, D., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111296 · Cited by 16
Parkinson's disease: pathogenesis and therapeutic strategies
Zhang, S., Wang, T., Peng, Y., Wang, Q., Zhang, Z., Shifeng, C. H. U., Huang, H., & Chen, N. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00445-0 · Cited by 21
Changes in Cognitive Function Following Bariatric Surgery: An Updated Systematic Review
Hathaway, I., Momodu, O. E., Williams, D. M., Beamish, A. J., Barry, J. D., & Stephens, J. W. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07235-z · Cited by 13
Semaglutide ameliorates diabetes-associated cognitive dysfunction in mouse model of type 2 diabetes
Zhu, Y., He, Y., Yang, H., Gao, Y., Wang, Y., Liu, P., & Zhang, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326897 · Cited by 18
Ballum, H., Dri, C. E., Liao, S., Yu, M., Le, G. H., Wong, S., Teopiz, K. M., Kwan, A. T. H., Ho, R., Choi, H., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121310 · Cited by 14
Si, J., Yu, K., Hao, J., Wang, J., & Zhang, L. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251332035 · Cited by 10
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Xu, Y., Drucker, D. J., Traverso, G., & Beloqui, A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf027 · Cited by 12
The impact of type 2 diabetes on aging: multidimensional approaches to preserve cognitive health
Lucia, S., Fornaro, S., Federici, M., & Rumiati, R. I. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02583-3 · Cited by 14
Giofrè, F., Zaffina, I., Pelle, M. C., & Arturi, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1696419 · Cited by 11
The critical role of GLP-1 signaling pathways in the pathology of Parkinson's disease and diabetes
Chen, J., Dong, X., Lin, Y., & Lv, C. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155985 · Cited by 7
Nance, N., Gilsanz, P., Karter, A. J., Finertie, H., Schmittdiel, J. A., An, J., Adams, A. S., Oshiro, C. E. S., Cassidy‐Bushrow, A. E., Dombrowski, S. K., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70621 · Cited by 9
Abdelhamid, A. H., Mantawy, E. M., Said, R. S., & El‐Demerdash, E. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116994 · Cited by 7
Correlations between Cognitive Evaluation and Metabolic Syndrome
Oprescu, A. C., Grosu, C., & Bild, W. (2023) · Metabolites · doi:10.3390/metabo13040570 · Cited by 7
Gong, Y., Luo, H., Li, Z., Feng, Y., Liu, Z., & Chang, J. (2023) · Metabolites · doi:10.3390/metabo13080954 · Cited by 7
Song, W., Xu, M., Sun, X., & Rao, X. (2023) · Medicine · doi:10.1097/md.0000000000035046 · Cited by 7
Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review
Ibrahim, R., Kambal, A., & Abdelmajeed, M. A. (2025) · Cureus · doi:10.7759/cureus.92441 · Cited by 11
Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial
Atieh, O., Daher, J., Abboud, M., Wu, Q., Sattar, A., Baissary, J., Koberssy, Z., Labbato, D. E., Eckard, A. R., & McComsey, G. A. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf577 · Cited by 10
GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review
Orozco, M. P., Rivadeneira, V. V., & León-Rojas, J. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412163 · Cited by 8
Gunta, U., Kandula, D. R., Gorti, S. K. K., Vadla, G. P., Kodiyala, G., & Mannarapu, M. (2023) · Oriental Journal Of Chemistry · doi:10.13005/ojc/390306 · Cited by 5
Sustained release of GLP-1 analog from γ-PGA-PAE copolymers for management of type 2 diabetes
Zhang, L., Jin, M., Pan, Y., Yang, F., Wu, Y., Gao, J., Chen, T., Tan, S., Yang, T., Chen, Y., et al. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213352 · Cited by 5
Su, Y., Zhang, S., Wu, Z., Liu, W.-T., Chen, J., Deng, F., Chen, F., Zhu, D., & Hou, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1054946 · Cited by 5
Salvatore, M., Zhang, B., Tang, H., Lu, Y., Zhang, D., Zhou, T., Lu, Y., Amaro, A., Ritchie, M. D., & Chen, Y. (2025) · medRxiv · doi:10.1101/2025.06.03.25328908 · Cited by 4
Je, I., Kim, T.-K., Lee, M. Y., Lee, M.-Y., An, K., Park, J.-T., & Kim, K.-Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178143 · Cited by 3
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 5
Jawad, A. N., Kadhim, K. A., Ali, Z. H., Fawzi, H. A., & Alzajaji, Q. B. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01537-3 · Cited by 2
Thome, A. D., Thonhoff, J. R., Wang, J., Berman, H., Grossman, F., & Appel, S. H. (2025) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2025-0001 · Cited by 1
Wicik, Z., Nowak-Szwed, A., Eyileten, C., Sourij, H., von Lewinski, D., Kistkins, S., Borkowska, J., & Postula, M. A. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00619-6 · Cited by 1
Targeting ER Stress of GLP-1 Receptor Agonist in Diabetic Retinopathy
Huang, H., Wang, Y., Gao, S., Li, N., Zhong, Y., & Shen, X. P. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117623 · Cited by 2
Zapp, C., Downer, D. M., Levine, A., Parker, N., Zapp, M., Downer, D. M., & Levine, L. (2026) · Cureus · doi:10.7759/cureus.102921 · Cited by 2
Verma, J., Singh, R. K., Paul, S., Gupta, S., Gupta, A. K., Sharma, A. K., Kumar, M., Mehan, S., Samant, R., & Tongra, M. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01866-0 · Cited by 1
Thome, A. D., Wang, J., Faridar, A., Zhao, W., Saetzler, V., Beers, D. R., & Appel, S. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177855 · Cited by 2
Xu, J., Chen, P., Wu, D., Zhou, Q., Chen, S., Ding, X., & Xiong, H. (2023) · Aging · doi:10.18632/aging.205118 · Cited by 3
Alolayan, S. A., & Alhowail, A. H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1638527 · Cited by 1
Yao, Y., Chen, L., Chen, X., Tian, X., & Zhou, W. J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4901779 · Cited by 1
Nielsen, T. A. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau588597746
Abdelhay, B., Aksissou, M., Elkhattabi, L., & Fait, S. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.09.010
Ichie, K. E., Asomugha, L. A., & Okafor, I. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.20.689379
Severini, G., Armentaro, G., Cassano, V., Condoleo, V., Pastura, C. A., Panza, A., Fuoco, C., Miceli, S., Fiorentino, T. V., Perticone, M., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1664988 · Cited by 1
The cellular and molecular pathophysiology of diabetes in aging
Namrata, N., Mundlia, P., Attri, D., Sharma, I., Sharma, A., & Giri, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44665-8.00008-0
A Preventive Neurology Perspective on Promoting Brain Health and Preventing Cardiovascular Disease
Murray, S., Akiyoshi, K., Isaacson, R., Dayspring, T. D., & Niotis, K. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.009
Pan, H.-Y., Liang, J.-X., Chen, W.-W., Sheng, Y.-Y., Zhang, W.-J., Zhu, X.-W., Wang, S.-Y., Yang, G.-H., Xu, B., & Xu, T.-C. (2026) · World Journal of Clinical Cases · doi:10.12998/wjcc.v14.i9.118295
GLP-1 and the brain’s powerhouse: a new perspective on the role of mitochondria in neuroprotection
Dasgupta, T., Bhayani, H., Ghoshdastidar, K., Viswanathan, K., & Jain, M. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01839-3 · Cited by 2
Accelerating the orphan GPCR pipeline: GPR149 as a case study in dual-domain target validation
Guth, M. A. S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104678
Mitochondrial remodeling as a effector of glp-1 therapy in obesity and diabetes: review
Alhindi, Y. Z. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/bfye5lnqza
Glycolysis: The Bridge Between Cellular Interaction and Alzheimer’s Disease
Lei, Q., He, Y., & Fang, B. (2026) · Biomolecules · doi:10.3390/biom16060796
Haidar, L., & Delaney, J. A. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001059 · Cited by 1
Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients
Lee, L. A., Tang, A. F., Asako, A., Ning, S., Reed, H. A., Duncan, E., Lugar, H. M., Hoekel, J., Marshall, B. A., Hershey, T. G., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1847818
Lin, C.-H., Hung, P., Chung, M., Wu, L.-Y., & Chung, C. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100645 · Cited by 2
Si, J., Wang, P., Li, Z., Hao, J., Wang, J., & Zhang, L. (2026) · Molecular Medicine · doi:10.1186/s10020-026-01616-z · Cited by 1
Heart Failure and Neurocognitive Disorders: A Narrative Review
Lin, S., Wang, Q., & Cao, J. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.126.014265
Popa, E., Popa, A. E., Poroch, V., Schreiner, T. G., Slănină, A. M., Poroch, M., Hatneanu, A. M., Ungureanu, M. I., Petroaie, A. D., Bacușcă, A. I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198738
Lakshmi, S. M., Singh, V., Vanangamudi, M., Taj, T., Shahin, H., Nath, R., Dutta, G., Avvari, S. K., Sridhar, S. B., Panigrahy, U. P., et al. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70718
Acquarone, E., Gutierrez, S. B. G., Zhang, H., Morin, A., Maccecchini, M. L., & Arancio, O. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70336
Metadata
- Authors
- Cheng, D., Yang, S., Zhao, X., & Wang, G.
- Affiliations
- First Hospital of Jilin University (CN)
- Corresponding author
- Wang, Guixia
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-03
- Volume
- Volume 16
- Pages
- 665-684
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC8943601
- OpenAlex
- W4221041575
- Cited by
- 84
- References
- 229
- Citations by year
- 2026: 21 · 2025: 27 · 2024: 13 · 2023: 18 · 2022: 5
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- People's Government of Jilin Province
- Jilin University
- First Hospital of Jilin University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- GLP-1 receptor agonists, neurodegenerative diseases, diabetes mellitus, Alzheimer's disease, Parkinson's disease, neuroprotection, type 2 diabetes, type 1 diabetes, obesity, cognitive impairment, molecular mechanisms
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Aged, Diabetes Mellitus, Type 2, Humans, Insulin, Neurodegenerative Diseases, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.